Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yitzhak Zimmer

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Molecular Cancer Therapeutics|November 8, 2024
HPV and p53 Status as Precision Determinants of Head and Neck Cancer Response to DNA-PKcs Inhibition in Combination with IrradiationLiana Hayrapetyan, Selina M Roth, Aurélie Quintin, et al.
Cell Death & Disease|April 7, 2021
Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injuryNicolas Melin, Daniel Sánchez-Taltavull, René Fahrner, et al.
Cancer Research|July 18, 2008
Coupling of mutated Met variants to DNA repair via Abl and Rad51Suganthini S Ganapathipillai, Michaela Medová, Daniel M Aebersold, et al.
Cellular and Molecular Life Sciences : CMLS|December 9, 2022
An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapiesEleonora Orlando, Matúš Medo, Ariel Bensimon, et al.
Molecular Oncology|April 27, 2020
Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomicsAriel Bensimon, Jonas P Koch, Paola Francica, et al.
Oncogene|May 3, 2018
Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxiaAstrid A Glück, Eleonora Orlando, Dominic Leiser, et al.
Oncogene|May 15, 2023
A DNA-PK phosphorylation site on MET regulates its signaling interface with the DNA damage responseJonas P Koch, Selina M Roth, Aurélie Quintin, et al.
Cancer Research Communications|July 3, 2024
E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response NetworkMichaela Poliaková Turan, Rahel Riedo, Matúš Medo, et al.
Oncogene|April 6, 2004
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variantsSylvie Berthou, Daniel M Aebersold, Laura S Schmidt, et al.
Cell Death & Disease|October 5, 2019
Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinomaJacopo Gavini, Noëlle Dommann, Manuel O Jakob, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Molecular Cancer Therapeutics|November 8, 2024
HPV and p53 Status as Precision Determinants of Head and Neck Cancer Response to DNA-PKcs Inhibition in Combination with IrradiationLiana Hayrapetyan, Selina M Roth, Aurélie Quintin, et al.
Cell Death & Disease|April 7, 2021
Synergistic effect of the TLR5 agonist CBLB502 and its downstream effector IL-22 against liver injuryNicolas Melin, Daniel Sánchez-Taltavull, René Fahrner, et al.
Cancer Research|July 18, 2008
Coupling of mutated Met variants to DNA repair via Abl and Rad51Suganthini S Ganapathipillai, Michaela Medová, Daniel M Aebersold, et al.
Cellular and Molecular Life Sciences : CMLS|December 9, 2022
An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapiesEleonora Orlando, Matúš Medo, Ariel Bensimon, et al.
Molecular Oncology|April 27, 2020
Deciphering MET-dependent modulation of global cellular responses to DNA damage by quantitative phosphoproteomicsAriel Bensimon, Jonas P Koch, Paola Francica, et al.
Oncogene|May 3, 2018
Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1α levels under hypoxiaAstrid A Glück, Eleonora Orlando, Dominic Leiser, et al.
Oncogene|May 15, 2023
A DNA-PK phosphorylation site on MET regulates its signaling interface with the DNA damage responseJonas P Koch, Selina M Roth, Aurélie Quintin, et al.
Cancer Research Communications|July 3, 2024
E2F1-Associated Purine Synthesis Pathway Is a Major Component of the MET-DNA Damage Response NetworkMichaela Poliaková Turan, Rahel Riedo, Matúš Medo, et al.
Oncogene|April 6, 2004
The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variantsSylvie Berthou, Daniel M Aebersold, Laura S Schmidt, et al.
Cell Death & Disease|October 5, 2019
Verteporfin-induced lysosomal compartment dysregulation potentiates the effect of sorafenib in hepatocellular carcinomaJacopo Gavini, Noëlle Dommann, Manuel O Jakob, et al.
Pageof 5